公开(公告)号：USRE49686E1

公开(公告)日：2023-10-10

申请号：US17076227

申请日：2020-10-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Junya Shirai ,  Hideyuki Sugiyama ,  Taku Kamei ,  Hironobu Maezaki

IPC: C07D401/04 ,  C07D207/14 ,  C07D211/58 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08

CPC classification number: C07D401/04 ,  C07D207/14 ,  C07D211/58 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08

Abstract: The present invention relates to a compound represented by the formula




wherein ring A is a nitrogen-containing heterocycle;

ring B is an aromatic ring optionally having substituent(s);

ring D is an aromatic ring optionally having substituent(s);

L is a group represented by the formula





R2, R3, R4a ′ and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain;
R1 is a hydrogen atom or a substituent;
m and n are each independently an integer of 0 to 5;
m+n is an integer of 2 to 5; and
is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

公开(公告)号：US11453661B2

公开(公告)日：2022-09-27

申请号：US17030504

申请日：2020-09-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro Ito ,  Hideyuki Sugiyama ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Jinxing Li ,  Junsi Wang ,  Takahito Kasahara ,  Masato Yoshikawa

IPC: C07D413/14 ,  A61P25/28 ,  C07D413/10

Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US11242348B2

公开(公告)日：2022-02-08

申请号：US16651840

申请日：2018-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Makoto Kamata ,  Hideyuki Sugiyama ,  Minoru Nakamura ,  Masataka Murakami ,  Shuhei Ikeda ,  Tomohiro Okawa ,  Hidekazu Tokuhara

IPC: C07D487/10 ,  A61P25/28 ,  A61K9/20 ,  A61K9/48

Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US10435399B2

公开(公告)日：2019-10-08

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro Ito ,  Hideyuki Sugiyama ,  Osamu Kubo ,  Fumiaki Kikuchi ,  Takeshi Yasui ,  Keiko Kakegawa ,  Zenichi Ikeda ,  Tohru Miyazaki ,  Yasuyoshi Arikawa ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Akinori Toita ,  Takuto Kojima ,  Yasutomi Asano ,  Ayumu Sato ,  Hironobu Maezaki ,  Shinobu Sasaki ,  Hironori Kokubo ,  Misaki Homma ,  Minoru Sasaki ,  Yasuhiro Imaeda

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D487/04 ,  A61P25/28 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US12084436B2

公开(公告)日：2024-09-10

申请号：US17426971

申请日：2020-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro Ito ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Hideyuki Sugiyama ,  Tohru Miyazaki ,  Yasuyoshi Arikawa ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Osamu Kubo ,  Akinori Toita ,  Takuto Kojima ,  Fumiaki Kikuchi ,  Minoru Sasaki ,  Misaki Homma ,  Yasuhiro Imaeda ,  Hironobu Maezaki ,  Shiinobu Sasaki ,  Ayumu Sato ,  Hirotaka Kamitani ,  Yasutomi Asano ,  Hironori Kokubo ,  Masato Yoshikawa

IPC: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US11958845B2

公开(公告)日：2024-04-16

申请号：US17952546

申请日：2022-09-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro Ito ,  Hideyuki Sugiyama ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Jinxing Li ,  Junsi Wang ,  Takahito Kasahara ,  Masato Yoshikawa

IPC: C07D413/14 ,  A61P25/28 ,  C07D413/10

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/10

Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：USRE48334E1

公开(公告)日：2020-12-01

申请号：US15445251

申请日：2017-02-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Junya Shirai ,  Hideyuki Sugiyama ,  Taku Kamei ,  Hironobu Maezaki

IPC: C07D401/04 ,  C07D207/14 ,  C07D211/58 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08

Abstract: The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R2, R3, R4a and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain; R1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

公开(公告)号：US10323026B2

公开(公告)日：2019-06-18

申请号：US15474192

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei Ikeda ,  Hideyuki Sugiyama ,  Jumpei Aida ,  Hidekazu Tokuhara ,  Tomohiro Okawa ,  Yuya Oguro ,  Minoru Nakamura ,  Masataka Murakami

IPC: C07D413/14 ,  C07D401/08 ,  C07D405/14 ,  C07D413/08 ,  C07D401/06 ,  C07D413/06

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US11274101B2

公开(公告)日：2022-03-15

申请号：US16651840

申请日：2018-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Makoto Kamata ,  Hideyuki Sugiyama ,  Minoru Nakamura ,  Masataka Murakami ,  Shuhei Ikeda ,  Tomohiro Okawa ,  Hidekazu Tokuhara

IPC: C07D487/10 ,  A61P25/28 ,  A61K9/20 ,  A61K9/48

Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US09624170B2

公开(公告)日：2017-04-18

申请号：US15108000

申请日：2014-12-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Makoto Fushimi ,  Jumpei Aida ,  Shuhei Ikeda ,  Tomokazu Kusumoto ,  Hideyuki Sugiyama ,  Hidekazu Tokuhara

IPC: C07D207/273 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D471/04 ,  C07D405/12 ,  C07D417/14 ,  C07D417/12 ,  C07D413/12 ,  C07D403/04 ,  C07D401/14

CPC classification number: C07D207/273 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.